Account-Based Marketing in Life Sciences
Account-Based Marketing in Life Sciences
Stop Marketing to Everyone.
Start Closing the Accounts That Matter.
Account-based marketing, or ABM, in life sciences is not a trend. It is the most commercially rational response to the most complex buyer journey in B2B. Here is how to build it correctly.
But first, here is a scenario I often see.
A life sciences marketing team invests six figures in a content program, drives respectable traffic to the website, generates a healthy volume of leads, and hands them to sales. Sales looks at the list and says: “These are not our buyers.” The cycle generally repeats the following quarter.
This disconnect is not a failure of effort. It is a failure of strategy. And in life sciences specifically, where a single enterprise health system, integrated delivery network, or biopharma partner can represent millions of dollars in long-term value, spraying content at a broad audience and hoping the right VP stumbles across it is not a plan. It is an expensive guess.
How to Reach Buyers in Life Sciences
Account-based marketing reframes the entire question. Instead of asking “how do we reach more people,” ABM asks “which specific organizations do we need to win, and what do the decision-makers need to believe before they say yes?” That shift, from volume to precision, changes everything about how you allocate budget, build content, run campaigns, and measure success.
In life sciences, one account won is worth more than a thousand unqualified leads. ABM is how you hunt with a scalpel instead of a net.
The Reality: Why Traditional Demand Generation Falls Short in Life Sciences
Most B2B marketing disciplines evolved in markets where the buying decision rests with one or two people, the sales cycle runs in weeks, and product complexity is manageable. Life sciences operates in almost the opposite environment in every dimension.
When a large academic medical center evaluates a new molecular diagnostic platform, the buying committee typically includes a medical director, a lab director, a supply chain officer, an informatics lead, and a C-suite sponsor. Each of these individuals holds different concerns, uses different language, evaluates different evidence, and participates at different stages of the decision. A generic email nurture sequence built around a single persona is irrelevant to most of them, most of the time.
The same dynamic plays out in commercial pharma partnerships. A biotech seeking a co-development agreement with a mid-sized pharma company is not selling to “a pharma company.” They are selling to a VP of Business Development who cares about deal structure, a Chief Medical Officer who cares about mechanism and unmet need, a Head of Commercial who cares about market size and competitive positioning, and a CFO who cares about risk-adjusted return. These are different conversations. They require different content. And they almost certainly need to happen in parallel.
6 – 10
Average stakeholders in a life sciences enterprise purchase decision
9+
Months in a typical enterprise life sciences sales cycle
208%
Greater revenue reported by companies with aligned ABM programs (ITSMA)
Traditional lead generation treats all of this complexity as a funnel problem. Generate more leads, and eventually the right ones will surface. ABM recognizes it as a precision problem. The goal is not more leads. The goal is deeper, earlier, and more coordinated engagement with the accounts you have already identified as high-value.
The Foundation: Build Your Ideal Account Profile Before You Build Anything Else
The most common ABM mistake I see life sciences companies make is skipping the account selection step. They hear that ABM means personalized content and targeted advertising, and they jump straight to execution. Two quarters later, they are running highly personalized campaigns toward accounts that were never going to convert, wondering why pipeline is not moving.
The Ideal Account Profile, or IAP, is not a persona. It is a description of the organizational characteristics that make an account likely to buy, likely to achieve value from your solution, and likely to become a long-term commercial relationship. In life sciences, that definition has several layers.
For diagnostics and medical device companies, your IAP might include:
- Hospital systems with a minimum number of annual test volume or procedure volume in the relevant service line
- Lab infrastructure that is compatible with your platform, or labs actively undergoing modernization
- Reimbursement environment and payer mix that supports adoption
- Organizations with a known history of early technology adoption or active clinical research programs
- Geographic markets where you have field coverage and can support onboarding
For biotech and pharma companies seeking commercial partnerships or licensing deals, your IAP criteria will look different, but the discipline is the same: build the profile from data, not intuition, and validate it against your existing wins before you build a target list.
A Note on Account Tiering
Not all target accounts deserve equal investment. Most ABM programs tier accounts into three categories.
Tier 1 accounts receive fully customized, one-to-one programs.
Tier 2 accounts receive industry-specific content and light personalization.
Tier 3 accounts receive programmatic ABM at scale, using behavioral signals to trigger relevant content.
Tier 1 programs often include custom clinical evidence packages, executive briefings, and dedicated field engagement. The resources required are significant, which is why most organizations can only support 10 to 20 true Tier 1 accounts at any given time.
The Science: Mapping the Buying Committee: The Part Most Marketers Skip
Once you have identified your target accounts, the next step is understanding who is in the buying committee for each one and what their decision criteria actually are. This is where scientific fluency pays its most direct commercial dividend.
In a health system evaluating a genomic testing platform, the lab director cares about analytical validity, turnaround time, and integration with the LIS. The medical director cares about clinical utility, guideline alignment, and patient outcomes. The supply chain officer cares about contract terms, vendor reliability, and transition risk. The informatics lead cares about interoperability, HL7 standards, and the burden on IT.
These are not variations on the same message. They are structurally different value stories. And if your content library contains only one version of “why our platform wins,” you are effectively communicating with one person in that room while the others sit in silence.
Example:
Foundation Medicine’s Multi-Stakeholder Playbook
When Foundation Medicine was building commercial traction for comprehensive genomic profiling in oncology, they recognized early that success required simultaneous engagement across multiple stakeholder types within a single health system. Oncologists needed evidence of clinical actionability. Pathologists needed confidence in analytical performance. Administrators needed the health economics story.
Their approach involved distinct content tracks for each audience, coordinated through field teams and digital channels, with content mapped to where each stakeholder sat in the decision process. The result was a shortened enterprise sales cycle and higher institutional adoption rates compared to programs that had relied on a single oncologist champion to carry the internal sell on their behalf. The science had to translate to every person in the room, not just the most enthusiastic one.
The Execution: What ABM Content Actually Looks Like in Life Sciences
One of the biggest misconceptions about ABM is that it requires building entirely custom content for every account. For Tier 1 accounts, some degree of customization is indeed necessary and worth the investment. But for most programs, ABM is less about building new content and more about assembling and contextualizing content you already have.
The question to ask for each target account is: what does this specific organization, given what we know about their current situation, their strategic priorities, and their buying stage, need to believe in order to move forward? Then work backward to the content that creates that belief.
Content formats that perform in life sciences ABM:
- Customized clinical evidence summaries that curate your most relevant data for a target account’s specific patient population or disease focus
- Account-specific ROI and health economics models built around the target organization’s own published data or publicly available operational benchmarks
- Peer reference case studies from similar institutions, ideally from the same IDN tier, teaching vs. community hospital category, or geographic market
- Executive briefing documents written in the language of administration and strategy rather than heavy on clinical science, designed for C-suite sponsors
- Regulatory and compliance documentation packaged in a format that accelerates procurement review, particularly for health systems with complex vendor credentialing processes
Example:
Illumina’s Account-Centric Sequencing Adoption Program
When Illumina worked to accelerate adoption of next-generation sequencing platforms in clinical laboratories, they faced a challenge that is a textbook case for ABM: the decision to convert from existing Sanger-based workflows to NGS required alignment across laboratory science, informatics, clinical operations, and administration simultaneously.
Their field-based ABM approach included customized lab assessments for each target institution, bioinformatics readiness reviews, and implementation roadmaps personalized to each lab’s existing infrastructure. Content was not broadcast broadly. It was built around each account’s specific starting point and delivered by specialists with the credibility to speak to each stakeholder’s concerns directly. Clinical adoption of their platforms in major academic medical centers accelerated meaningfully in accounts where this coordinated, account-centric approach was applied.
The Channel Strategy: Where and How to Reach Life Sciences Buyers
ABM in life sciences operates across a different channel mix than most B2B sectors, because life sciences buyers consume information differently. Physicians and scientists validate claims through peer review and collegial networks before they trust commercial sources. Administrators follow a different path, driven by trade publications, conference learning, and vendor briefings.
The channels that move the needle:
LinkedIn and programmatic display
Account-based advertising on LinkedIn, using account lists matched to the platform’s company targeting capabilities, allows you to serve relevant content to specific individuals within target organizations as they move through their awareness and consideration process. This works particularly well for surfacing thought leadership content to administrative and business development audiences who spend meaningful time on the platform.
Medical conference and event activation
For physician and scientific audiences, conferences remain the highest-trust touchpoint outside of peer referral. ABM programs should map major conference calendars and build pre-event, at-event, and post-event engagement sequences for target accounts with attendees. The goal is not the booth conversation alone. It is the sequence of interactions across six months that turns a conference encounter into a sales conversation.
Direct and field-coordinated outreach
In enterprise sales, the sales rep is a marketing channel. ABM programs that equip field teams with account-specific content packages, talking points calibrated to each stakeholder, and clear intelligence on what the account has already consumed perform dramatically better than programs where marketing and sales operate in separate lanes.
Scientific and clinical content publishing
White papers, clinical application notes, outcomes data summaries, and peer-reviewed reprints distributed to specific accounts through digital and direct channels serve a dual purpose in ABM: they build credibility with scientific evaluators and create visible intent signals when tracked through marketing automation.
Intent Data in Life Sciences
One of the most underused tools in life sciences ABM is third-party intent data. Platforms like Bombora and TechTarget track content consumption across thousands of B2B sites and can surface signals that a specific organization is actively researching topics relevant to your solution. When a target health system suddenly shows elevated research activity around “genomic sequencing reimbursement” or “LIS integration for molecular diagnostics,” that is a buying signal, and it warrants an immediate, coordinated response. In a long sales cycle market, being first to show up when a prospect is actively looking is a meaningful competitive advantage.
Measuring ABM the Right Way in Life Sciences
ABM measurement requires a different framework than traditional demand generation. When you are running a program with 50 to 150 target accounts, volume-based metrics like cost per lead and total lead count tell you almost nothing useful. What you need to track is engagement quality and pipeline movement within your defined account universe.
The metrics that actually matter in a life sciences ABM program are account engagement score (a composite measure of the number of stakeholders engaging within an account, the frequency and depth of their engagement, and the recency of activity), account progression rate (the percentage of target accounts advancing from one stage of the buying journey to the next over a defined period), influenced pipeline (the total value of opportunities that have experienced meaningful marketing touchpoints during their active sales cycle), and win rate among target accounts versus non-ABM sourced deals.
This last metric is often the most persuasive internal evidence for the value of ABM. When organizations measure their close rate on accounts that received coordinated ABM treatment against their baseline close rate on comparable inbound or cold-outbound deals, the difference is typically substantial. It is not uncommon to see ABM-influenced close rates two to three times higher than non-ABM baselines in complex enterprise sales, precisely because the buyer has been educated, their objections have been anticipated, and their entire committee has been engaged.
Example:
A Regional Diagnostics Company Rewrites Its Pipeline Story
A mid-sized specialty diagnostics company we work with had spent years running broad inbound marketing programs, generating solid website traffic and a reasonable volume of leads, but struggling to convert enterprise health system accounts. When we mapped their existing closed deals, a clear pattern emerged: nearly every significant enterprise win had involved multiple coordinated touchpoints across at least three stakeholders at the target organization, with content specifically tailored to the lab, clinical, and administrative perspectives.
They had been doing ABM accidentally, inconsistently, and without a framework. We helped them formalize it: building a tiered account list of 80 target health systems, developing a multi-stakeholder content architecture across three buying roles, standing up account-based advertising to create ambient awareness, and equipping field teams with account dossiers before every engagement. Within twelve months, their average deal size increased by 34% and their sales cycle on enterprise accounts shortened by two months. The product had not changed. The precision of their commercial approach had.
The Strategic Imperative: ABM Is Not a Marketing Tactic. It Is a Commercial Philosophy.
I want to be direct about something. ABM is not a software platform you purchase, a campaign type you run for a quarter, or a reporting dashboard you configure. It is a fundamental realignment of how your commercial organization identifies, pursues, and wins the accounts it needs to grow.
That means sales and marketing have to operate as a genuinely integrated function, sharing account intelligence, agreeing on what a “good” account looks like, holding joint accountability for account pipeline, and building feedback loops so marketing knows when the content is landing and when it is not. In organizations where sales and marketing remain organizationally siloed, ABM rarely reaches its potential regardless of how sophisticated the technology stack is.
It also means being willing to accept that in a well-executed ABM program, you will generate fewer leads than a broad demand generation program. Your CEO or CFO may push back on that during the first reporting cycle. The response to that pushback is account-level pipeline data: the revenue in motion within your target account universe, the quality of stakeholders engaged, and the progression of specific accounts toward close. Volume is the wrong metric. Value is the only one that matters.
“The companies winning in life sciences commercialization are not the ones with the most content. They are the ones who know exactly which 80 accounts they need to win this year and have a specific plan for each one.”
Brad Saeed, President, BTS Consulting
Next Steps
Life sciences is a field defined by precision. The instruments you sell or the therapies you support are built on the idea that targeting the right mechanism, at the right concentration, in the right patient population is categorically different from a broad intervention applied indiscriminately. Your commercial strategy deserves that same level of precision. Account-based marketing is how you apply it.
Ready to Build an ABM Program That Actually Converts?
BTS Consulting works with life sciences companies to build account-based strategies grounded in scientific fluency, commercial rigor, and the kind of buyer intelligence that closes enterprise deals.
By Teri Krause, VP Operations & Client Services
Teri Krause is a healthcare and life sciences marketing strategist with more than a decade of experience helping organizations elevate visibility, strengthen relationships, and drive growth. At BTS Consulting, she manages client relationships, oversees vendor deliverables, and partners with creative teams to deliver high-quality campaigns. Teri has led successful initiatives for leading pharma, biotech, diagnostics, and medical device companies, as well as hospitals, insurers, and nonprofits. Her work has supported national campaigns, product launches, and branding strategies for organizations including Exact Sciences, QIAGEN, GE Medical, Mayo Clinic, United Healthcare, and more.
